ASH 2020

Complete Coverage

TOURMALINE-MM2: Ixazomib Plus Lenalidomide and Dexamethasone for Newly Diagnosed MM

A phase 3 trial showed a trend toward improved PFS with ixazomib plus lenalidomide and dexamethasone.

Prognostic Biomarker Testing in CLL/SLL Remains Low

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

Prognostic Biomarker Testing in CLL/SLL Remains Low

Clinicians are not following guideline recommendations, as prognostic biomarker testing for CLL/SLL remains low and affects treatment selection.

Liso-Cel Plus Ibrutinib Demonstrated Efficacy in R/R CLL/SLL

A phase 1 trial demonstrated antitumor activity of liso-cel plus ibrutinib with low rates of grade 3 or higher CRS and neurotoxicity among heavily pretreated patients with CLL/SLL.

Umbralisib Plus Ublituximab Improved PFS vs Chemoimmunotherapy in CLL

The phase 3 UNITY-CLL study showed prolonged PFS with the PI3K inhibitor plus anti-CD20 therapy combination.

Promising Efficacy Seen With LOXO-305 in R/R CLL/SLL

LOXO-305 treatment of heavily pretreated CLL/SLL resulted in durable, high response rates in a phase 1/2 trial.

Older Patients With NHL Are at Higher Risk for Hospitalization vs Non-Cancer Controls

The average spending per hospitalization during the course of 5 years was higher for survivors of NHL compared with controls ($16,950 vs. $13,474).

Interim Analysis Shows Benefit of First-Line Axi-Cel in High-Risk LBCL

Axi-cel demonstrated significant clinical benefit as a first-line treatment for patients with high-risk large B-cell lymphoma.

Bispecific CAR-T Therapy Found to Have Promising Efficacy in Older Patients With R/R B-Cell NHL

The bispecific CAR-T therapy targets CD20 and CD19.

Response Rates in Phase 1 Studies of Hematologic Malignancies Improved Over Time

Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.

Real-World Data: Ibrutinib Improves Outcomes vs Chemoimmunotherapy in CLL

Ibrutinib was associated with a longer duration until second-line treatment, regardless of risk status, compared with CIT among patients with CLL.

Hospitalization Burden of Patients with Multiple Myeloma

Hospitalization due to MM has increased over the last 10 years, but in-hospital mortality has declined.

Fully Human BCMA-Directed CAR-T Shows High Response Rate in Myeloma

A fully human BCMA-directed CAR-T product showed clinical activity in patients with relapsed/refractory multiple myeloma.

Sustained CLL Response Seen With Ibrutinib Plus Venetoclax After MRD Negativity

Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.

CAR-T Product With Unique Manufacturing Process Appears Safe in the Outpatient Setting

A CAR-T therapy for myeloma that is manufactured using a unique process showed clinical activity and appeared safe, even in the outpatient setting.

Venetoclax-Rituximab Led to Sustained MRD Negativity in R/R CLL

The combination was also associated with improvements in progression-free and overall survival.

Fixed Duration Ibrutinib-Venetoclax for CLL Resulted in High Rate of Undetectable MRD

Confirmed undetectable MRD after 12 cycles may result in treatment discontinuation.

STAMP Inhibitor May Be a New Treatment Option in CML

Asciminib may be a new treatment option for patients with chronic myeloid leukemia in the chronic phase (CML-CP).

Posttransplant Azacitidine for High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome

There may be no relapse-free survival or overall survival benefits with posttransplant azaciditine in patients with high-risk AML or MDS.

Discontinuation of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

Study results suggested that the discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia may be safe, without limiting remission.